Clinical trials
Lymphoblastic Leukemia clinical trials
Below are recruiting lymphoblastic leukemia clinical trials, each written for real people, not researchers. We’re tracking 381 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06648889RecruitingPhase 2
Isatuximab for CD38 positive T-cell ALL
This trial tests if the drug isatuximab can help adults with a type of T-cell leukemia (T-ALL) that has come back or hasn't fully responded to treatment, or has minimal remaining disease after chemotherapy. The treatment targets a protein called CD38 found on the leukemia cells.
AugsburgAges 18 years+ - NCT07684131Recruiting
Observational study of Philadelphia-positive ALL treatments
This study follows adults with Philadelphia chromosome-positive ALL who are receiving a combination of targeted therapy (a BCR::ABL1 inhibitor) and other treatments. It collects real-world data to better understand how these treatments work.
AmiensAges 18 years+ - NCT06718244RecruitingPhase 2
CNCT19 for B-ALL with minimal remaining cancer after first remission
This trial tests a CAR-T cell therapy (CNCT19) for people with B-cell acute lymphoblastic leukemia (B-ALL) who still have a tiny amount of cancer cells after standard treatment. The goal is to see if this therapy can clear those remaining cancer cells.
Shanghai, Shanghai MunicipalityAges 16–70 - NCT06742515RecruitingPhase 2
Blinatumomab with lower-dose chemo for B-ALL
This trial tests a combination of a targeted drug (blinatumomab) with a lower dose of standard chemotherapy for adults newly diagnosed with a certain type of B-cell acute lymphoblastic leukemia. The goal is to see if this approach is effective and causes fewer side effects than full-dose chemotherapy.
Hangzhou, ZhejiangAges 15–59 - NCT06754267RecruitingPhase 2
Studying a new drug combo for Ph+ B-ALL
This trial tests a combination of three drugs (venetoclax, olverembatinib, and prednisone) for adults newly diagnosed with Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia (Ph+ B-ALL). The goal is to see if this combination is safe and effective.
Hangzhou, ZhejiangAges 18 years+ - NCT06819475Recruiting
Muscle health study for childhood leukemia survivors
This study uses imaging to look at how well the mitochondria (the tiny power plants inside your muscle cells) are working. It compares survivors of childhood leukemia who have low muscle mass to healthy volunteers, to understand muscle health and find ways to help.
Memphis, TennesseeAges 18 years+ - NCT06863259RecruitingPhase 1
Study of a drug combo for relapsed B-cell leukemia
This trial tests a combination of three drugs (Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone) for children and young adults whose B-cell acute lymphoblastic leukemia (B-ALL) has come back after treatment. It may help those whose leukemia has not responded to standard therapy or who have relapsed after a stem cell transplant or CAR-T therapy.
Cincinnati, OhioAges 1–39 - NCT06866873Recruiting
CAR-T cell therapy for kids with ALL or lymphoma
This trial tests a special immune cell treatment (CAR-T cells) for children whose leukemia or lymphoma has come back or not responded to at least two prior treatments. The goal is to see if these cells can find and destroy the cancer.
Hong KongAges 1–17 - NCT06879340RecruitingPhase 1
Testing a new CAR-T therapy for B-cell blood cancers
This study tests a new CAR-T cell therapy called DuoCAR20.19.22-D95 for people with certain blood cancers (like lymphoma and ALL) that have come back or haven't responded to multiple treatments. It aims to see if this therapy is safe and can help shrink or control the cancer.
Westwood, KansasAges 18 years+ - NCT06886074RecruitingPhase 2
Short blinatumomab to clear leftover B-ALL cells
This trial tests if a shorter course of blinatumomab can remove minimal residual disease (MRD) — tiny traces of leukemia not seen under a microscope — in people with B-cell acute lymphoblastic leukemia after initial treatment.
Monterrey, Nuevo LeónAges 16–60 - NCT06961669Recruiting
CD19 CAR-T cells for B-cell cancers and multiple myeloma
This trial tests a personalized treatment where your own immune cells are modified to target and kill cancer cells that have a protein called CD19. It is for patients with certain types of B-cell lymphoma, B-cell acute leukemia, or multiple myeloma that has come back or not responded to previous treatment.
HefeiAges 3 years+ - NCT06985485RecruitingPhase 2
Immunotherapy for older or frail B-ALL patients
This trial tests a full course of immunotherapy (drugs that help your immune system fight cancer) instead of intensive chemotherapy for people with B-cell acute lymphoblastic leukemia (B-ALL) who are older or cannot tolerate strong chemo. It aims to offer an effective, less toxic option.
Suzhou, JiangsuAges 15 years+ - NCT07048535Recruiting
Long-term follow-up study for CAR T-cell therapy patients
This study follows children and young adults who received CAR T-cell therapy for B-cell ALL at least two years ago. It checks long-term side effects, how well the therapy worked over time, and quality of life, so doctors can better understand the lasting impacts of CAR T-cells.
Memphis, TennesseeAges Any age - NCT07059156RecruitingPhase 2/Phase 3
Chemotherapy and transplant for adult ALL
This trial is testing a combination of chemotherapy and stem cell transplant for adults with Acute Lymphoblastic Leukemia (ALL). It aims to find the best way to treat ALL and improve survival. If you are diagnosed with ALL and are between 18 and 60 years old, you may be a candidate.
Taiyuan, ShanxiAges 18–60 - NCT07066397RecruitingPhase 1
CAR-T cell therapy for relapsed B-cell ALL
This trial tests a new CAR-T cell therapy (FIT-CD19-CAR-T) for adults with B-cell acute lymphoblastic leukemia that has come back or not responded to treatment. The goal is to see if this treatment is safe and can help control the leukemia.
TaipeiAges 18 years+ - NCT07072494RecruitingPhase 1/Phase 2
CD19 CAR-T cells as consolidation for B-cell ALL
This trial tests a single infusion of CD19 CAR-T cells as a consolidation treatment to keep leukemia in remission for patients who are not eligible for or decline a stem cell transplant. The goal is to see if this therapy can prevent relapse.
Guangzhou, GuangdongAges 14–80 - NCT07108868RecruitingPhase 1
Study of MB-CART2219.1 for blood cancers
This trial tests a new CAR T-cell therapy called MB-CART2219.1 in people with certain types of blood cancer (like lymphoma or leukemia) that have come back or not responded to other treatments. CAR T-cells are your own immune cells that are modified to better find and kill cancer cells.
Tübingen, Baden-WurttembergAges 12–75 - NCT07203352RecruitingPhase 3
Targeted drugs plus chemo for T-cell acute lymphoblastic leukemia
This trial tests whether adding targeted drugs to standard chemotherapy works better for adults newly diagnosed with T-ALL. If you have not had any prior treatment for leukemia, this study might be an option.
Guangzhou, GuangdongAges 18–70 - NCT07228741RecruitingPhase 2
Exercise and medicine for heart health in ALL survivors with obesity
This trial tests if combining resistance exercise with the weight-loss medication tirzepatide can improve heart and metabolic health in survivors of childhood acute lymphoblastic leukemia (ALL) who are now adults and have obesity or overweight with related health issues. You may benefit if you finished treatment at least 2 years ago and meet weight and health criteria.
Memphis, TennesseeAges 18 years+ - NCT07239323RecruitingPhase 1
CAR-T therapy for blood cancers that have returned or not responded
This trial tests a new CAR-T cell therapy for people with certain blood cancers (B-cell acute lymphoblastic leukemia, B-cell lymphoma, or multiple myeloma) that have come back or stopped responding to treatment. The therapy uses your own immune cells, modified in a lab to attack cancer cells, then given back to you intravenously.
Kunming, YunnanAges 18 years+ - NCT07284927RecruitingPhase 1
LV009 injection for blood and lymph cancers
This trial tests a new treatment called LV009, a type of CAR-T cell therapy, for people with certain blood cancers (like leukemia or lymphoma) that have CD19 on their cells. The therapy uses your own immune cells to fight the cancer.
Suzhou, JiangsuAges 18–70 - NCT07312630RecruitingEarly Phase 1
A study of LV009 for certain blood cancers
This trial tests an experimental treatment called LV009 for people with certain types of blood cancers that have come back or not responded to previous treatments. The treatment targets a protein called CD19 found on cancer cells.
Hefei, AnhuiAges 18–70 - NCT07327138Recruiting
Laughter and yoga for kids with leukemia after chemo
This study tests if fun yoga and laughter exercises at home can help children aged 2-10 with a type of leukemia feel less pain after chemotherapy. It's designed to be gentle and safe, with a parent or guardian joining in.
SidonAges 2–10 - NCT07454226Recruiting
Drug combo for Ph-like acute lymphoblastic leukemia
This trial tests a combination of targeted drugs (ABL/JAK inhibitors) with chemotherapy and venetoclax for people with a type of leukemia called Ph-like ALL. It aims to see if this treatment is safe and effective.
Tianjin, Tianjin MunicipalityAges 14–60
Hear when a new Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lymphoblastic leukemia?
- Yes. Clin2 currently lists 381 recruiting lymphoblastic leukemia studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lymphoblastic leukemia trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lymphoblastic leukemia trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
- Acute Lymphoblastic Leukemia
- B-cell Acute Lymphoblastic Leukemia
- Refractory Acute Lymphoblastic Leukemia
- T-cell Acute Lymphoblastic Leukemia
- Acute Lymphoblastic Leukemia, in Relapse
- Acute Lymphoblastic Leukemia, Adult
- T Acute Lymphoblastic Leukemia
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.